

REMARKS

The Examiner requires a restriction of the claimed invention, and lists the following group classifications:

Group	Claims	Description
I	1-3 & 6-8	methods comprising providing target cells for recovering a ligand from an activated target cell
II	4 & 5	an acute lymphoblastic leukemia cell of claims of Group I
III	9-11 & 14-16	methods comprising providing an isolation means for recovering a ligand from an activated target cell
IV	12 & 13	an acute lymphoblastic leukemia cell of claims of Group III

Applicant hereby elects to prosecute the claims of Group I, *without traverse*, and with the election of apoptosis as the species of cellular response and Annexin V as the species of indicator, for initial examination purposes. Applicant hereby amends Claims 4, 5 and 8, and cancels Claims 9-16, in order to further the prosecution of the present application and Applicant's business interests, without acquiescing to the Examiner's arguments, and while reserving the right to prosecute the original, similar, or broader claims in one or more future application(s). In particular, Applicant has amended dependent Claims 4 and 5 as method claims, such that Claims 1-8 all belong in Group I. In addition, Applicant has amended Claim 8 to indicate that in some embodiments when apoptosis is the cellular response being detected, that Annexin V is used as an indicator. Support for the amendment to Claim 8 can be found but is not limited to Example 1.

Applicant respectfully requests consideration of the references listed on the Information Disclosure Statement submitted herewith. However, should the Examiner believe a telephone

interview would aid in the prosecution of this application, Applicant encourages the Examiner to call the undersigned collect.

Dated: August 1, 2007



Christine A. Lekutis
Registration No. 51,934

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
415.904.6500